Last 7 days
-4.0%
Last 30 days
29.8%
Last 90 days
15.2%
Trailing 12 Months
5317.4%
Datesorted ascending | Name | Buy/Sell | $ Value | Avg. Price | # Shares | Title |
---|---|---|---|---|---|---|
2023-03-17 | COHEN RON | bought | 6,500 | 0.65 | 10,000 | president and ceo |
2023-03-16 | COHEN RON | bought | 6,093 | 0.6 | 10,156 | president and ceo |
2022-09-03 | Clem Kerry M | sold (taxes) | -601 | 0.398 | -1,511 | chief commercial officer |
2022-09-03 | Sabella Lauren M | sold (taxes) | -601 | 0.398 | -1,511 | chief operating officer |
2022-03-17 | COHEN RON | sold | -3,894 | 1.7014 | -2,289 | president and ceo |
2021-09-03 | Morales Robert | sold (taxes) | -1,962 | 4.38 | -448 | interim pao & pfo |
2021-09-03 | Sabella Lauren M | sold (taxes) | -6,618 | 4.38 | -1,511 | chief commercial officer |
2021-09-03 | COHEN RON | sold (taxes) | -17,257 | 4.38 | -3,940 | president and ceo |
2021-03-03 | BLANK BURKHARD | acquired | - | - | 11,125 | cmo and head of r&d |
2021-03-03 | Sabella Lauren M | acquired | - | - | 11,125 | chief commercial officer |
Datesorted ascending | Fund Name | Type | % Chg | $ Change | $ Held | % Portfolio |
---|---|---|---|---|---|---|
2023-09-12 | DAVIDSON KEMPNER CAPITAL MANAGEMENT LP | sold off | -100 | -1,009,720 | - | -% |
2023-09-12 | DAVIDSON KEMPNER CAPITAL MANAGEMENT LP | new | - | 716,885 | 716,885 | 0.02% |
2023-08-21 | OSAIC HOLDINGS, INC. | new | - | 13.00 | 13.00 | -% |
2023-08-21 | ADVISOR GROUP HOLDINGS, INC. | sold off | -100 | - | - | -% |
2023-08-15 | WELLS FARGO & COMPANY/MN | new | - | 48,657 | 48,657 | -% |
2023-08-15 | WELLS FARGO & COMPANY/MN | sold off | -100 | -43,804 | - | -% |
2023-08-14 | Royal Bank of Canada | new | - | 7,000 | 7,000 | -% |
2023-08-14 | DEUTSCHE BANK AG\ | new | - | 22,117 | 22,117 | -% |
2023-08-14 | Royal Bank of Canada | sold off | -100 | - | - | -% |
2023-08-14 | VANGUARD GROUP INC | sold off | -100 | -93,630 | - | -% |
Date Filed | Name of Filer | Percent of Class | No. of Shares | Form Type | |
---|---|---|---|---|---|
May 10, 2023 | davidson kempner capital management lp | 0.13% | 31,311 | SC 13D/A | |
Mar 10, 2023 | davidson kempner capital management lp | 0.21% | 51,189 | SC 13D/A | |
Feb 14, 2023 | canyon capital advisors llc | 0.00% | 0 | SC 13G/A | |
Feb 13, 2023 | renaissance technologies llc | 3.57% | 868,892 | SC 13G/A | |
Jan 23, 2023 | davidson kempner capital management lp | 0.24% | 59,129 | SC 13D/A | |
Jun 10, 2022 | soros fund management llc | 0% | 0 | SC 13G | |
Jun 10, 2022 | davidson kempner capital management lp | 0.28% | 68,229 | SC 13D | |
Feb 14, 2022 | ubs oconnor llc | 0% | 0 | SC 13G/A | |
Feb 14, 2022 | point72 asset management, l.p. | 4.1% | 464,276 | SC 13G/A | |
Feb 14, 2022 | canyon capital advisors llc | 5.79% | 649,031 | SC 13G/A |
Date Filed | Form Type | Document | |
---|---|---|---|
Aug 09, 2023 | 10-Q | Quarterly Report | |
Aug 08, 2023 | 8-K | Current Report | |
Jun 27, 2023 | 8-K | Current Report | |
Jun 26, 2023 | 8-K | Current Report |
Name | Mkt Capsorted ascending | Revenue | Price %, 1M | Returns, 1Y | P/E | P/S | Rev 1-Yr | Inc 1-Yr |
---|---|---|---|---|---|---|---|---|
LARGE-CAP | ||||||||
AMGN | 143.8B | 26.6B | 4.22% | 19.52% | 18.02 | 5.41 | 0.75% | 21.34% |
GILD | 93.5B | 27.4B | -3.50% | 20.95% | 17.04 | 3.41 | -0.48% | 32.56% |
MRNA | 39.4B | 10.7B | -11.43% | -12.52% | 32.6 | 3.69 | -53.67% | -91.41% |
BIIB | 37.2B | 10.0B | -3.81% | -2.75% | 13.96 | 3.73 | -6.23% | 29.40% |
MID-CAP | ||||||||
NBIX | 11.0B | 1.7B | 3.79% | 9.48% | 62.24 | 6.56 | 29.01% | 1345.90% |
BBIO | 4.3B | - | -13.26% | 158.53% | -7.29 | 48.33 | 54.84% | -12.96% |
DNLI | 2.8B | - | -11.57% | -29.57% | -22.07 | 37.44 | 122.90% | 54.78% |
BEAM | 1.9B | 80.2M | 2.30% | -49.37% | -5.73 | 23.39 | 42.17% | -39.82% |
SMALL-CAP | ||||||||
RCUS | 1.3B | 121.2M | -10.65% | -29.69% | -4.65 | 11.03 | -70.36% | -531.73% |
REPL | 1.0B | 15.3M | -19.06% | 2.95% | -5.55 | 65.91 | 1090.59% | -36.57% |
NVAX | 682.8M | 1.6B | -13.40% | -61.01% | -1.16 | 0.43 | 23.74% | 60.24% |
FATE | 208.9M | - | -19.70% | -90.51% | -0.99 | 1.53 | 116.83% | 16.61% |
VXRT | 114.6M | 2.1M | -6.34% | -64.60% | -1.14 | 55.76 | 487.70% | -8.66% |
SGMO | 104.6M | - | -36.73% | -87.68% | -0.53 | 0.43 | 113.96% | -15.19% |
IBIO | 6.2M | - | -2.07% | -93.34% | -0.08 | 3.21 | - | -129.46% |
-23.3%
-26.2%
-33.8%
64.9%
100%
100%
100%
Y-axis is the maximum loss one would have experienced if Acorda Therapeutics was unfortunately bought at previous high price.
Income Statement (Last 12 Months) | ||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Description | (%) Q/Q | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 | 2018Q4 | 2018Q3 | 2018Q2 |
Revenue | -1.2% | 116,914,000 | 118,290,000 | 118,566,000 | 124,063,000 | 122,008,000 | 122,742,000 | 129,071,000 | 130,263,000 | 151,897,000 | 153,730,000 | 152,967,000 | 165,303,000 | 159,935,000 | 176,370,000 | 192,408,000 | 211,064,000 | 306,156,000 | 409,405,000 | 471,433,000 | 590,679,000 | 588,930,000 |
Costs and Expenses | -7.9% | 136,744,000 | 148,403,000 | 153,906,000 | 171,229,000 | 187,194,000 | 189,702,000 | 208,109,000 | 276,137,000 | 258,725,000 | 254,419,000 | 231,043,000 | 150,500,000 | 420,519,000 | 450,793,000 | 504,040,000 | 586,483,000 | 393,928,000 | 414,753,000 | 432,947,000 | 720,971,000 | 749,678,000 |
S&GA Expenses | -8.1% | 93,590,000 | 101,832,000 | 106,256,000 | 108,442,000 | 115,068,000 | 117,369,000 | 124,399,000 | 128,835,000 | 139,147,000 | 145,435,000 | 152,576,000 | 160,923,000 | 169,690,000 | 181,229,000 | 192,846,000 | 188,441,000 | 183,310,000 | 177,378,000 | 172,254,000 | 174,954,000 | 172,124,000 |
R&D Expenses | 0.5% | 5,521,000 | 5,496,000 | 5,804,000 | 5,968,000 | 6,516,000 | 7,365,000 | 10,420,000 | 13,377,000 | 17,175,000 | 20,056,000 | 23,012,000 | 27,712,000 | 38,056,000 | 51,760,000 | 60,083,000 | 78,118,000 | 84,900,000 | 91,851,000 | 106,383,000 | 114,467,000 | 124,898,000 |
EBITDA | -100.0% | - | 32,552,000 | 27,762,000 | -12,640,000 | -30,149,000 | -33,002,000 | -45,086,000 | -110,011,000 | -68,507,000 | -60,219,000 | -35,795,000 | 112,529,000 | -163,486,000 | -176,584,000 | -217,803,000 | -343,945,000 | -62,804,000 | 12,367,000 | 53,499,000 | -113,048,000 | -141,376,000 |
EBITDA Margin | -100.0% | - | 0.28 | 0.23 | -0.10 | -0.25 | -0.27 | -0.35 | -0.84 | -0.45 | -0.39 | -0.23 | 0.68 | -1.02 | -1.00 | -1.13 | -1.63 | -0.21 | 0.03 | 0.11 | -0.19 | -0.24 |
Interest Expenses | 1.0% | 30,508,000 | 30,209,000 | 30,200,000 | 29,839,000 | 29,541,000 | 29,772,000 | 30,035,000 | 30,461,000 | 31,054,000 | 30,833,000 | 30,574,000 | 28,380,000 | 25,120,000 | 23,014,000 | 21,872,000 | 21,573,000 | 22,488,000 | 22,524,000 | 21,597,000 | 21,207,000 | 19,972,000 |
Earnings Before Taxes | 29.4% | -21,072,000 | -29,845,000 | -35,247,000 | -75,720,000 | -93,458,000 | -96,734,000 | -109,074,000 | -176,333,000 | -137,345,000 | -130,800,000 | -107,667,000 | 43,354,000 | -228,976,000 | -239,398,000 | -274,248,000 | -392,576,000 | -105,001,000 | -23,176,000 | 20,423,000 | -149,123,000 | -179,507,000 |
EBT Margin | 100.0% | - | -0.25 | -0.30 | -0.61 | -0.77 | -0.79 | -0.85 | -1.35 | -0.90 | -0.85 | -0.70 | 0.26 | -1.43 | -1.36 | -1.43 | -1.86 | -0.34 | -0.06 | 0.04 | -0.25 | -0.30 |
Net Income | 64.1% | -20,917,000 | -58,218,000 | -65,916,000 | -105,625,000 | -118,842,000 | -95,024,000 | -103,954,000 | -166,440,000 | -132,022,000 | -126,579,000 | -99,600,000 | 49,114,000 | -221,768,000 | -231,833,000 | -272,966,000 | -329,031,000 | -79,407,000 | -5,724,000 | 33,682,000 | -146,977,000 | -158,261,000 |
Net Income Margin | 100.0% | - | -0.49 | -0.56 | -0.85 | -0.97 | -0.77 | -0.81 | -1.28 | -0.87 | -0.82 | -0.65 | 0.30 | -1.39 | -1.31 | -1.42 | -1.56 | -0.26 | -0.01 | 0.07 | -0.25 | -0.27 |
Free Cashflow | 100.0% | - | -14,441,000 | -21,060,000 | -26,887,000 | -34,033,000 | -28,273,000 | -41,513,000 | -43,620,000 | -37,365,000 | -51,288,000 | -65,396,000 | -91,969,000 | -132,707,000 | -157,466,000 | -218,593,000 | -216,270,000 | -106,358,000 | -8,580,000 | 117,465,000 | 197,798,000 | 181,521,000 |
Balance Sheet | (In Millions) | |||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Description | (%) Q/Q | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 | 2018Q4 | 2018Q3 | 2018Q2 |
Assets | -2.7% | 365 | 375 | 396 | 393 | 406 | 424 | 455 | 466 | 491 | 584 | 633 | 710 | 728 | 754 | 800 | 880 | 1,197 | 1,234 | 1,300 | 1,311 | 1,251 |
Current Assets | -4.7% | 65.00 | 68.00 | 82.00 | 72.00 | 77.00 | 80.00 | 102 | 97.00 | 113 | 190 | 221 | 152 | 158 | 168 | 201 | 314 | 358 | 418 | 528 | 547 | 495 |
Cash Equivalents | -16.5% | 25.00 | 30.00 | 38.00 | 21.00 | 23.00 | 32.00 | 46.00 | 36.00 | 46.00 | 117 | 71.00 | 58.00 | 41.00 | 32.00 | 62.00 | 120 | 148 | 197 | 294 | 321 | 243 |
Inventory | 9.9% | 15.00 | 13.00 | 13.00 | 15.00 | 15.00 | 15.00 | 19.00 | 21.00 | 25.00 | 27.00 | 29.00 | 30.00 | 33.00 | 26.00 | 25.00 | 27.00 | 28.00 | 31.00 | 29.00 | - | - |
Net PPE | -9.2% | 2.00 | 2.00 | 3.00 | 3.00 | 3.00 | 4.00 | 4.00 | 5.00 | 6.00 | 6.00 | 7.00 | 139 | 142 | 143 | 143 | 131 | 113 | 83.00 | 61.00 | 52.00 | 43.00 |
Goodwill | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 281 | 280 | 282 | 283 | 284 |
Current Liabilities | -12.5% | 30.00 | 35.00 | 38.00 | 42.00 | 41.00 | 46.00 | 54.00 | 68.00 | 68.00 | 133 | 137 | 139 | 138 | 71.00 | 86.00 | 92.00 | 94.00 | 97.00 | 140 | 136 | 121 |
Shareholder's Equity | -11.8% | 68.00 | 77.00 | 94.00 | 76.00 | 88.00 | 128 | 151 | 164 | 190 | 206 | 238 | 314 | 291 | 307 | 311 | 281 | 545 | 567 | 612 | 599 | 607 |
Retained Earnings | -1.0% | -962 | -953 | -936 | -955 | -941 | -894 | -870 | -849 | -822 | -799 | -766 | -683 | -690 | -673 | -666 | -732 | -468 | -441 | -393 | -403 | -389 |
Additional Paid-In Capital | 0.0% | 1,030 | 1,030 | 1,030 | 1,030 | 1,029 | 1,024 | 1,023 | 1,016 | 1,016 | 1,008 | 1,008 | 1,000 | 983 | 981 | 979 | 1,015 | 1,012 | 1,009 | 1,005 | 1,000 | 993 |
Shares Outstanding | 2.1% | 1.00 | 1.00 | - | 1.00 | 1.00 | 1.00 | - | 1.00 | 0.00 | 0.00 | - | 0.00 | 0.00 | 0.00 | - | 0.00 | 0.00 | 0.00 | - | 0.00 | 0.00 |
Cashflow (Last 12 Months) | (In Millions) | |||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Description | (%) Q/Q | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 | 2018Q4 | 2018Q3 | 2018Q2 |
Cashflow From Operations | 20.7% | -11.35 | -14.30 | -20.92 | -26.75 | -33.92 | -28.10 | -41.35 | -43.14 | -37.03 | -49.11 | -61.01 | -73.88 | -95.33 | -89.45 | -128 | -129 | -26.55 | 45.00 | 151 | 224 | 197 |
Share Based Compensation | -31.8% | 1.00 | 1.00 | 1.00 | 2.00 | 2.00 | 3.00 | 3.00 | 4.00 | 6.00 | 7.00 | 8.00 | 9.00 | 10.00 | 13.00 | 14.00 | 17.00 | 18.00 | 19.00 | 21.00 | 24.00 | 25.00 |
Cashflow From Investing | - | - | - | -0.14 | -0.26 | -0.11 | -0.18 | 74.00 | 79.00 | 99.00 | 122 | 59.00 | 110 | 87.00 | 29.00 | -0.50 | -71.33 | -70.77 | -83.41 | -176 | -162 | -161 |
Cashflow From Financing | - | - | - | - | - | - | - | -69.65 | -69.65 | -69.74 | -0.74 | -1.67 | -61.54 | -61.45 | -61.49 | -60.55 | -0.62 | 2.00 | 11.00 | 13.00 | 67.00 | 66.00 |
Buy Backs | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 0.00 | 0.00 | 0.00 | 1.00 | 2.00 | 2.00 | 2.00 |
Consolidated Statements of Operations - USD ($) shares in Thousands, $ in Thousands | 3 Months Ended | 6 Months Ended | ||
---|---|---|---|---|
Jun. 30, 2023 | Jun. 30, 2022 | Jun. 30, 2023 | Jun. 30, 2022 | |
Revenues: | ||||
Total net revenues | $ 29,675 | $ 31,051 | $ 51,933 | $ 53,585 |
Costs and expenses: | ||||
Cost of sales | 3,065 | 8,800 | 6,299 | 14,768 |
Research and development | 1,550 | 1,525 | 2,936 | 3,219 |
Selling, general and administrative | 21,825 | 30,067 | 44,339 | 57,005 |
Amortization of intangible assets | 7,691 | 7,691 | 15,382 | 15,382 |
Change in fair value of derivative liability | (7) | (37) | ||
Changes in fair value of acquired contingent consideration | (824) | (3,110) | (1,915) | (6,133) |
Total operating expenses | 33,307 | 44,966 | 67,041 | 84,204 |
Operating loss | (3,632) | (13,915) | (15,108) | (30,619) |
Other income (expense), net: | ||||
Interest and amortization of debt discount expense | (7,773) | (7,474) | (15,344) | (15,036) |
Interest income | 58 | 20 | 151 | 21 |
Other income | 2 | 1,250 | 94 | 1,250 |
Realized loss on foreign currency transactions | (1) | (1) | ||
Total other expense, net | (7,714) | (6,204) | (15,100) | (13,765) |
Loss before taxes | (11,346) | (20,119) | (30,208) | (44,384) |
Benefit from (provision for) income taxes | 1,965 | (26,563) | 4,003 | (26,821) |
Net loss | $ (9,381) | $ (46,682) | $ (26,205) | $ (71,205) |
Net loss per share—basic | $ (7.55) | $ (54.01) | $ (21.10) | $ (97.33) |
Net loss per share—diluted | $ (7.55) | $ (54.01) | $ (21.10) | $ (97.33) |
Weighted average common shares outstanding used in computing net loss per share-basic | 1,242 | 864 | 1,242 | 732 |
Weighted average common shares outstanding used in computing net loss per share-diluted | 1,242 | 864 | 1,242 | 732 |
Net Product Revenues | ||||
Revenues: | ||||
Total net revenues | $ 25,965 | $ 27,484 | $ 44,684 | $ 46,059 |
Royalty Revenues | ||||
Revenues: | ||||
Total net revenues | 3,687 | $ 3,567 | 7,215 | $ 7,526 |
License revenues | ||||
Revenues: | ||||
Total net revenues | $ 23 | $ 34 |
Consolidated Balance Sheets - USD ($) $ in Thousands | Jun. 30, 2023 | Dec. 31, 2022 |
---|---|---|
Current assets: | ||
Cash and cash equivalents | $ 25,270 | $ 37,536 |
Restricted cash | 828 | 6,884 |
Trade accounts receivable, net of allowances of $875 and $842, as of June 30, 2023 and December 31, 2022, respectively | 13,390 | 13,866 |
Prepaid expenses | 5,480 | 4,312 |
Inventory, net | 14,797 | 12,752 |
Other current assets | 5,149 | 6,765 |
Total current assets | 64,914 | 82,115 |
Property and equipment, net of accumulated depreciation | 2,163 | 2,603 |
Intangible assets, net of accumulated amortization | 289,700 | 305,087 |
Right of use asset, net of accumulated amortization | 4,765 | 5,287 |
Restricted cash | 255 | 255 |
Other non-current assets | 2,899 | 248 |
Total assets | 364,696 | 395,595 |
Current liabilities: | ||
Accounts payable | 3,175 | 9,809 |
Accrued expenses and other current liabilities | 21,822 | 23,680 |
Current portion of lease liabilities | 1,567 | 1,545 |
Current portion of acquired contingent consideration | 3,274 | 2,532 |
Deferred revenue | 548 | 384 |
Total current liabilities | 30,386 | 37,950 |
Convertible senior notes | 176,164 | 167,031 |
Non-current portion of acquired contingent consideration | 35,226 | 38,668 |
Non-current portion of lease liabilities | 3,764 | 4,341 |
Deferred tax liability | 39,556 | 44,202 |
Other non-current liabilities | 11,732 | 9,781 |
Stockholders’ equity: | ||
Preferred stock, $0.001 par value per share. Authorized 1,000,000 shares at June 31, 2023 and December 31, 2022; no shares issued as of June 30, 2023 and December 31, 2022, respectively | ||
Common stock, $0.001 par value per share. Authorized 3,083,333 shares at June 30, 2023 and December 31, 2022; issued 1,242,376 shares,including those held in treasury, as of June 30, 2023 and December 31, 2022, respectively | 1 | 24 |
Treasury stock at cost (278 shares at June 30, 2023 and December 31, 2022) | (638) | (638) |
Additional paid-in capital | 1,030,103 | 1,029,881 |
Accumulated deficit | (962,478) | (936,273) |
Accumulated other comprehensive income | 880 | 628 |
Total stockholders’ equity | 67,868 | 93,622 |
Total liabilities and stockholders’ equity | $ 364,696 | $ 395,595 |